University of California MOG Peptide Glioblastoma Patent Application
Summary
The Regents of the University of California published European patent application EP4054596A1 on April 15, 2026, covering the use of MOG peptide for priming glioblastoma treatment. The application names six inventors and includes ten IPC classifications spanning peptide sequences, cancer therapeutics, and cellular immunotherapies across 31 designated contracting states.
About this source
GovPing monitors EPO Patent Bulletin - Peptides (C07K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 22 changes logged to date.
What changed
European patent application EP4054596A1 has been published by the European Patent Office, establishing a priority date and formal publication record for The Regents of the University of California's MOG peptide invention directed at glioblastoma treatment. The application is now publicly accessible and will proceed through EPO examination.
Pharmaceutical companies and researchers developing cancer immunotherapies should review this filing for freedom-to-operate considerations. Academic institutions conducting related immunotherapy research may need to assess potential overlaps with their own programmes. Healthcare providers treating glioblastoma patients are not directly affected but should be aware of the evolving IP landscape for emerging treatment modalities.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
USE OF MOG FOR PRIMING A TREATMENT FOR GLIOBLASTOMA
Publication EP4054596A1 Kind: A1 Apr 15, 2026
Applicants
The Regents of the University of California
Inventors
ROYBAL, Kole T., LIM, Wendell A., SIMIC, Milos, OKADA, Hideho, CHOE, Joseph H., WATCHMAKER, Payal B.
IPC Classifications
A61K 35/12 20150101AFI20231018BHEP A61K 35/14 20150101ALI20231018BHEP A61K 35/17 20150101ALI20231018BHEP A61P 35/00 20060101ALI20231018BHEP C07K 14/705 20060101ALI20231018BHEP C07K 14/725 20060101ALI20231018BHEP C12N 15/62 20060101ALI20231018BHEP C07K 14/71 20060101ALI20231018BHEP A61K 35/15 20150101ALI20231018BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.